论文部分内容阅读
患者男,72岁,因头昏、乏力、畏寒、活动后气促1年,近1周加重,于1991年3月1日入院。既往无特殊。体检:中度贫血貌、面部轻度浮肿,余均正常。实验室检查:Hb75g/L,RBC2.63×10~(12)/L,WBC1.5×10~9/L、BPC80×10~9/L。骨髓增生活跃(低水平),粒、红2系呈病态造血,原粒0.12、早幼粒0.185,提示:骨髓增生异常综合征—原始粒细胞增多的难治性贫血(MDS—RAEB)。1991年3月20日开始用全反式维甲酸(at-RA)诱导分化治疗,药物由上海瑞金医院提供,批号为910225。剂量:60mg/d,分3次口服,至服药第14天出
Male, 72 years old, due to dizziness, fatigue, chills, postponed activity 1 year, nearly 1 week aggravating, in March 1, 1991 admission. No special past. Physical examination: moderate anemia appearance, facial mild edema, more than normal. Laboratory tests: Hb75g / L, RBC2.63 × 10 ~ (12) / L, WBC1.5 × 10 ~ 9/L, BPC80 × 10 ~ 9 / L. Bone marrow hyperplasia (low level), granulocyte, red 2 was pathological hematopoietic, the original grain 0.12, promyelotic 0.185, suggesting: myelodysplastic syndrome - refractory anemia (MGS-RAEB). March 20, 1991 began all-trans retinoic acid (at-RA) induction of differentiation treatment, the drug provided by Shanghai Ruijin Hospital, lot number 910225. Dosage: 60mg / d, 3 times orally, to the medication on the 14th day out